Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

Mar 08, 2022
Dr. Pamela Kunz discusses her editorial priorities at JCO and the collaborative efforts that will advance equity in the selection of meeting abstracts.
Feb 22, 2022
Dr. Peppercorn will begin serving as the editor designee of JCO OP on March 1, 2022, and as editor-in-chief on September 1. 
Jan 14, 2022
A new payment model in radiation oncology takes effect in January 2022 and will make significant strides towards transitioning Medicare reimbursement models into an episode-based payment system for certain cancers. 
Sep 01, 2021
A novel approach to address financial toxicity, published in JCO Oncology Practice, features the first Financial Toxicity Tumor Board developed by the Levine Cancer Institute in North Carolina.
Aug 06, 2021
When Dr. Bosserman began her tenure as editor-in-chief in January 2019, she expanded the publication’s priorities of care delivery and quality improvement while addressing issues of equity and value. 
Jun 30, 2021
Although progress has been made in the United States over the past 20 years to lower cancer incidence and mortality, Black Americans have the highest death rate and shortest survival of any racial and ethnic group in the U.S. for most cancers.
Jun 23, 2021
In a recently published special article in JCO Global Oncology, the authors present City Cancer Challenge’s (C/Can) framework for strengthening cancer care in cities in low- and middle-income countries and explain how it is implemented.
May 03, 2021
Outgoing editor-in-chief Dr. Stephen A. Cannistra will end his term in June 2021 confident in JCO’s future, he said, knowing the journal will be in the highly capable hands of incoming editor-in-chief Dr. Jonathan W. Friedberg.
Mar 09, 2021
The series explores themes including improving allogeneic stem cell transplantation through increased donor availability and innovative transplant technology, novel cellular therapies such as CAR-T, the application of checkpoint inhibition, and other insights.
Jan 15, 2021
A new special series includes guidance on factors and decision-making processes for selecting the right platform, how to reduce expenses from manual burdens, and how to allocate resources to successfully enable NGS for clinical cancer care. 

Pages